EU HTA Joint Clinical Assessment: are patients with rare disease going to lose out?

J Comp Eff Res. 2024 May 2:e240052. doi: 10.57264/cer-2024-0052. Online ahead of print.

Authors

Alejandra Castanon¹, Rebecca Sloan¹, Luisamanda Selle Arocha¹, Sreeram V Ramagopalan^{1

2}

Affiliations

¹ Lane Clark & Peacock LLP, London, W1U 9DQ, UK.
² Centre for Pharmaceutical Medicine Research, King's College London, London, SE1 9NH, UK.

PMID: 38696698
DOI: 10.57264/cer-2024-0052

No abstract available

Keywords: EU HTA; JCA; RWE; indirect comparison; joint clinical assessment; real-world evidence.

Publication types

Editorial